Aziyo Biologics is a commercial-stage regenerative medicine company. Co.'s Core Products include: CanGaroo, which is a biological envelope that remodels into systemically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic devices; and ProxiCor, Tyke and VasCure, which are portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. Co.'s Non-Core Products include the contract manufacturing of particulate bone, milled bone, cellular bone matrix, acellular dermis, amnion and other soft tissue products. The AZYO stock yearly return is shown above.
The yearly return on the AZYO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AZYO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|